DaVita Inc. (NYSE:DVA) Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd decreased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 48.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,661 shares of the company's stock after selling 21,364 shares during the period. WINTON GROUP Ltd's holdings in DaVita were worth $3,389,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. Amundi raised its stake in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after purchasing an additional 240,126 shares during the last quarter. KBC Group NV lifted its holdings in shares of DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after purchasing an additional 2,636 shares during the period. BNP Paribas Financial Markets grew its position in DaVita by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company's stock valued at $47,874,000 after buying an additional 56,389 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after buying an additional 12,339 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Remove Ads

DaVita Price Performance

DaVita stock traded down $1.15 during mid-day trading on Tuesday, reaching $151.82. The company had a trading volume of 718,532 shares, compared to its average volume of 809,341. The stock's 50-day simple moving average is $156.77 and its 200-day simple moving average is $157.44. The company has a market capitalization of $12.15 billion, a P/E ratio of 14.14, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on DVA shares. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, StockNews.com cut DaVita from a "buy" rating to a "hold" rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.